The conference brings together investors, analysts and industry experts to highlight the most exciting trends within the life science sector. In addition to a market update, three listed companies developing innovative solutions will also present.

Jonas Jönmark’s presentation is scheduled for 16:55–17:25.

“We look forward to introducing AcuCort to Danish investors and industry colleagues, as well as providing an update on our business and future plans. This is especially exciting now that our product Zeqmelit® has recently been launched on the Danish market. The conference is an important forum for engaging with investors and other stakeholders in our sector,” says Jonas Jönmark, CEO of AcuCort.

More information and registration for the conference can be found here:
https://konferencer.ugebrev.dk/event/investor-konference-den-24-september/

For further information: 
Jonas Jönmark, vd, AcuCort AB
Phone: 070 365 5400
E-mail: jonas.jonmark@acucort.se

About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.